BCRX FY 2017 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

FY 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$25M-4.4% YoY

Gross Profit

$23M93.2% margin

Operating Income

-$57M-227.9% margin

Net Income

-$66M-261.2% margin

EPS (Diluted)

$-0.78

Cash Flow

Operating Cash Flow

-$41M

Free Cash Flow

-$41M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$178M

Total Liabilities

$94M

Stockholders' Equity

-$632M

Cash & Equivalents

$50M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$25M	$26M	-4.4%
Gross Profit	$23M	$24M	-0.7%
Operating Income	-$57M	-$49M	-18.1%
Net Income	-$66M	-$55M	-19.3%